Wednesday, July 27, 2016

BRIEF-Anavex presents 31-week efficacy data from Alzheimer's phase 2a study

* Anavex presents 31-week efficacy data from phase 2a study

of ANAVEX 2-73 in alzheimer's patients at AAIC 2016

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)